Research Analysts Offer Predictions for Talphera Q2 Earnings

Talphera, Inc. (NASDAQ:TLPH) – Investment analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Talphera in a research report issued to clients and investors on Friday, June 5th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Talphera’s Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.10) EPS and FY2030 earnings at $0.34 EPS.

Other equities research analysts have also recently issued reports about the company. Westpark Capital started coverage on Talphera in a report on Thursday, April 30th. They set a “buy” rating and a $3.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Talphera in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.00.

Talphera Price Performance

Shares of TLPH stock opened at $0.78 on Monday. Talphera has a 12-month low of $0.38 and a 12-month high of $1.57. The company has a market capitalization of $40.22 million, a P/E ratio of -2.50 and a beta of 0.76. The firm has a 50-day moving average price of $0.81 and a 200 day moving average price of $0.95.

Talphera (NASDAQ:TLPH) last issued its earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TLPH. Rosalind Advisors Inc. grew its position in shares of Talphera by 118.9% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after buying an additional 2,381,818 shares during the period. Nantahala Capital Management LLC lifted its holdings in Talphera by 75.3% in the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock valued at $3,120,000 after buying an additional 1,500,000 shares during the period. Empery Asset Management LP bought a new position in Talphera in the fourth quarter valued at approximately $1,520,000. Cantor Fitzgerald L. P. acquired a new stake in Talphera during the 4th quarter worth $658,000. Finally, Renaissance Technologies LLC grew its holdings in Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after acquiring an additional 207,166 shares during the period. Institutional investors own 37.67% of the company’s stock.

Insider Buying and Selling

In other news, CEO Vincent J. Angotti acquired 213,310 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was purchased at an average cost of $0.59 per share, for a total transaction of $125,852.90. Following the completion of the transaction, the chief executive officer directly owned 800,705 shares in the company, valued at $472,415.95. This trade represents a 36.31% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.50% of the stock is currently owned by insiders.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.